guest ::
| Home > Publications Database > Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies > print |
| Home > Publications Database > Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies > print |
| 001 | 268860 | ||
| 005 | 20240808164504.0 | ||
| 024 | 7 | _ | |a pmid:38612794 |2 pmid |
| 024 | 7 | _ | |a 10.3390/ijms25073984 |2 doi |
| 024 | 7 | _ | |a 1422-0067 |2 ISSN |
| 024 | 7 | _ | |a 1661-6596 |2 ISSN |
| 024 | 7 | _ | |a pmc:PMC11012515 |2 pmc |
| 037 | _ | _ | |a DZNE-2024-00359 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Stahl, Fabian |0 P:(DE-2719)2812610 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies |
| 260 | _ | _ | |a Basel |c 2024 |b Molecular Diversity Preservation International |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1713178962_9658 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The spinocerebellar ataxias (SCA) comprise a group of inherited neurodegenerative diseases. Machado-Joseph Disease (MJD) or spinocerebellar ataxia 3 (SCA3) is the most common autosomal dominant form, caused by the expansion of CAG repeats within the ataxin-3 (ATXN3) gene. This mutation results in the expression of an abnormal protein containing long polyglutamine (polyQ) stretches that confers a toxic gain of function and leads to misfolding and aggregation of ATXN3 in neurons. As a result of the neurodegenerative process, SCA3 patients are severely disabled and die prematurely. Several screening approaches, e.g., druggable genome-wide and drug library screenings have been performed, focussing on the reduction in stably overexpressed ATXN3(polyQ) protein and improvement in the resultant toxicity. Transgenic overexpression models of toxic ATXN3, however, missed potential modulators of endogenous ATXN3 regulation. In another approach to identify modifiers of endogenous ATXN3 expression using a CRISPR/Cas9-modified SK-N-SH wild-type cell line with a GFP-T2A-luciferase (LUC) cassette under the control of the endogenous ATXN3 promotor, four statins were identified as potential activators of expression. We here provide an overview of the high throughput screening approaches yet performed to find compounds or genomic modifiers of ATXN3(polyQ) toxicity in different SCA3 model organisms and cell lines to ameliorate and halt SCA3 progression in patients. Furthermore, the putative role of cholesterol in neurodegenerative diseases (NDDs) in general and SCA3 in particular is discussed. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Machado-Joseph Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Translational Research, Biomedical |2 MeSH |
| 650 | _ | 2 | |a Spinocerebellar Ataxias: genetics |2 MeSH |
| 650 | _ | 2 | |a Translational Science, Biomedical |2 MeSH |
| 650 | _ | 2 | |a Animals, Genetically Modified |2 MeSH |
| 650 | _ | 7 | |a ASO |2 Other |
| 650 | _ | 7 | |a CRISPR/Cas |2 Other |
| 650 | _ | 7 | |a SREBP |2 Other |
| 650 | _ | 7 | |a cholesterol |2 Other |
| 650 | _ | 7 | |a clinical trials |2 Other |
| 650 | _ | 7 | |a compound modifier |2 Other |
| 650 | _ | 7 | |a genomic modifier |2 Other |
| 650 | _ | 7 | |a high throughput screening |2 Other |
| 650 | _ | 7 | |a miRNA |2 Other |
| 650 | _ | 7 | |a spinocerebellar ataxia 3 (SCA3) |2 Other |
| 650 | _ | 7 | |a transcriptional and posttranscriptional regulation |2 Other |
| 700 | 1 | _ | |a Evert, Bernd O. |b 1 |
| 700 | 1 | _ | |a Han, Xinyu |b 2 |
| 700 | 1 | _ | |a Breuer, Peter |0 P:(DE-2719)9002874 |b 3 |u dzne |
| 700 | 1 | _ | |a Wüllner, Ullrich |0 P:(DE-2719)2000056 |b 4 |e Last author |
| 770 | _ | _ | |a CNS Drug Action in Neurodegenerative Diseases 3.0 |
| 773 | _ | _ | |a 10.3390/ijms25073984 |g Vol. 25, no. 7, p. 3984 - |0 PERI:(DE-600)2019364-6 |n 7 |p 3984 |t International journal of molecular sciences |v 25 |y 2024 |x 1422-0067 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/268860/files/DZNE-2024-00359.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/268860/files/DZNE-2024-00359.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:268860 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2812610 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)9002874 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2000056 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-25 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-25 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J MOL SCI : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J MOL SCI : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-07-07T16:31:47Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-07-07T16:31:47Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-25 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-25 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-07-07T16:31:47Z |
| 920 | 1 | _ | |0 I:(DE-2719)1011302 |k AG Wüllner |l Biomarker Parkinson's Disease |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1011302 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|